TOKYO, May 15 (Pulse News Wire) – Phoenixbio Co., Ltd. (6190.T) reported consolidated results for fiscal year 2026 ending March.
Revenue was ¥1.6 billion (+1.6% YoY). operating profit was ¥82 million.
Net profit was ¥125 million. Total assets stood at ¥2.2 billion with an equity ratio of 70.2%.
The full-year forecast for the current fiscal year is revenue of ¥1.6 billion (+2.9%).
Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥1,565M | +1.6% |
| Operating profit | ¥82M | n/a |
| Net profit | ¥125M | n/a |
Next period forecast
Revenue
¥1,610M
+2.9%Op. profit
¥85M
+3.7%Net profit
¥76M
-38.6%Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.